z-logo
Premium
Malignant mouse melanoma cells do not form tumors when mixed with cells of a non‐malignant subclone: Relationships between plasminogen activator expression by the tumor cells and the host's immune response
Author(s) -
Newcomb Elizabeth W.,
Silverstein Samuel C.,
Silagi Selma
Publication year - 1978
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.1040950206
Subject(s) - plasminogen activator , biology , cancer research , in vitro , melanoma , immune system , clone (java method) , activator (genetics) , cell culture , immunology , microbiology and biotechnology , endocrinology , receptor , biochemistry , dna , genetics
Mouse melanoma clones B 5 59 and B78 are highly tumorigenic when injected into C57BL/6J mice. Tumor formation by these cells is suppressed when they are mixed with nonmalignant bromodeoxyuridine‐grown clone C 3 471 before injection. C 3 471 cells suppress tumor formation only in immunocompetent hosts; mixtures of B 5 59 and C 3 471 cells or C 3 471 cells alone form tumors in antithymocyte serum (ATS)‐treated mice. Explants of C 3 471 tumors grown in ATS‐treated mice form tumors in immunocompetent mice, most of which regress. Inability of C 3 471 or mixtures of C 3 471 with malignant cells to grow in normal mice, as contrasted with ability to grow in immunosuppressed mice, indicates that host response is involved. Both tumorigenic clones have high plasminogen activator activity, whereas nontumorigenic clone C 3 471 has none. Mixture of either tumorigenic clone with C 3 471 cells decreases plasminogen activator in vitro. C 3 471 tumor explants from ATS‐treated mice initially express plasminogen activator, but lose the capacity to express this activity upon prolonged cultivation in vitro. Explants from B 5 59 tumors retain plasminogen activator in long term culture. Close physical contact between C 3 471 and B 5 59 cells appears essential both for inhibition of plasminogen activator expression by B 5 59 cells in vitro, and for tumor suppression in vivo. These findings suggest that production of plasminogen activators by tumor cells may play an important role in suppressing the host's immune response locally to an inoculum of syngeneic tumor cells.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom